SI2706982T1 - Intranasal pharmaceutical dosage forms comprising naloxone - Google Patents

Intranasal pharmaceutical dosage forms comprising naloxone Download PDF

Info

Publication number
SI2706982T1
SI2706982T1 SI201231239T SI201231239T SI2706982T1 SI 2706982 T1 SI2706982 T1 SI 2706982T1 SI 201231239 T SI201231239 T SI 201231239T SI 201231239 T SI201231239 T SI 201231239T SI 2706982 T1 SI2706982 T1 SI 2706982T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical
amount
pharmaceutical formulation
use according
application liquid
Prior art date
Application number
SI201231239T
Other languages
English (en)
Slovenian (sl)
Inventor
John Strang
Alexander Oksche
Stephen Harris
Kevin Smith
Lucie Helene Jeanne Mottier
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44658496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2706982(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of SI2706982T1 publication Critical patent/SI2706982T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI201231239T 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone SI2706982T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166076 2011-05-13
PCT/EP2012/058792 WO2012156317A2 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone
EP12721507.7A EP2706982B2 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone

Publications (1)

Publication Number Publication Date
SI2706982T1 true SI2706982T1 (en) 2018-05-31

Family

ID=44658496

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231239T SI2706982T1 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone

Country Status (37)

Country Link
US (7) US20150018379A1 (enExample)
EP (2) EP2706982B2 (enExample)
JP (3) JP6110367B2 (enExample)
KR (2) KR101873174B1 (enExample)
CN (2) CN107260672A (enExample)
AR (1) AR086391A1 (enExample)
AT (1) AT16553U1 (enExample)
AU (2) AU2012257785B2 (enExample)
BR (1) BR112013029126A2 (enExample)
CA (1) CA2835940C (enExample)
CO (1) CO6821959A2 (enExample)
CY (1) CY1120399T1 (enExample)
DE (1) DE202012013606U1 (enExample)
DK (2) DK2706982T4 (enExample)
ES (1) ES2661838T5 (enExample)
HK (1) HK1255428A1 (enExample)
HR (1) HRP20180233T1 (enExample)
HU (1) HUE036465T2 (enExample)
IL (1) IL229409B (enExample)
LT (1) LT2706982T (enExample)
ME (1) ME02958B (enExample)
MX (1) MX354249B (enExample)
MY (1) MY194947A (enExample)
NO (1) NO2706982T3 (enExample)
PH (2) PH12013502313A1 (enExample)
PL (1) PL2706982T3 (enExample)
PT (1) PT2706982T (enExample)
RS (1) RS57054B1 (enExample)
RU (2) RU2587051C2 (enExample)
SG (1) SG194927A1 (enExample)
SI (1) SI2706982T1 (enExample)
SM (1) SMT201800105T1 (enExample)
TR (1) TR201802716T4 (enExample)
TW (1) TWI486161B (enExample)
UA (1) UA110974C2 (enExample)
WO (1) WO2012156317A2 (enExample)
ZA (1) ZA201308280B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
EP2706982B2 (en) * 2011-05-13 2021-03-10 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone
WO2015095644A1 (en) * 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
DE112015001251T5 (de) 2014-03-14 2017-01-19 Opiant Pharmaceuticals Inc. Nasale Arzneimittelprodukte und Verfahren zu deren Verwendung
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US11135155B2 (en) * 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US20160008277A1 (en) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US11559483B2 (en) * 2015-07-10 2023-01-24 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
CA2950687C (en) * 2015-09-17 2023-02-28 Adapt Pharma Limited Nasal drug products and methods of their use
MX2018015985A (es) * 2016-06-24 2019-09-13 Opiant Pharmaceuticals Inc Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.
EP3500261A4 (en) * 2016-08-17 2020-05-06 Hikma Pharmaceuticals USA Inc. LIQUID NALOXONE SPRAYING
CN114144224B (zh) 2019-03-26 2024-08-09 保科特纳洛克斯恩公司 药物合成物输送器械和方法
WO2020198327A1 (en) * 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US20230201369A1 (en) * 2020-04-29 2023-06-29 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
IL297658A (en) 2020-05-18 2022-12-01 Orexo Ab Pharmaceutical preparation for drug administration
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023014906A1 (en) 2021-08-04 2023-02-09 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
KR20240103005A (ko) 2021-11-25 2024-07-03 오렉쏘 에이비 아드레날린을 포함하는 약학적 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
FI20012462A7 (fi) 1999-06-16 2002-01-16 Nastech Pharm Co Farmaseuttisia formulaatioita ja menetelmiä käsittäen intranasaalista morfiinia
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US8017627B2 (en) * 2000-07-31 2011-09-13 Nycomed Danmark Aps Fentanyl composition for nasal administration
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CN1674903A (zh) 2002-07-11 2005-09-28 大鹏药品工业株式会社 经鼻吸收用组合物
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
CN1575795A (zh) * 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
EP1785145A4 (en) 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
CN100524037C (zh) * 2004-11-09 2009-08-05 皇家飞利浦电子股份有限公司 空间光调制器阵列和制造空间光调制器设备的方法
CA2587792C (en) * 2004-12-23 2010-07-06 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
RU2344822C2 (ru) * 2006-04-05 2009-01-27 Алексей Валентинович Надеждин Способ лечения героиновой наркомании
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
CN106389330A (zh) * 2007-01-19 2017-02-15 哈南亚有限公司 用于递送治疗剂的方法和组合物
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
EP2706982B2 (en) * 2011-05-13 2021-03-10 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
DE112015001251T5 (de) 2014-03-14 2017-01-19 Opiant Pharmaceuticals Inc. Nasale Arzneimittelprodukte und Verfahren zu deren Verwendung
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray

Also Published As

Publication number Publication date
RU2013155479A (ru) 2015-06-20
AU2016204880A1 (en) 2016-07-28
US20190374464A1 (en) 2019-12-12
NZ705933A (en) 2016-07-29
KR101873174B1 (ko) 2018-06-29
JP6110367B2 (ja) 2017-04-05
EP2706982B1 (en) 2018-01-03
US20240082149A1 (en) 2024-03-14
ME02958B (me) 2018-07-20
AR086391A1 (es) 2013-12-11
HRP20180233T1 (hr) 2018-06-01
NO2706982T3 (enExample) 2018-06-02
SG194927A1 (en) 2013-12-30
US12458591B2 (en) 2025-11-04
KR20140007482A (ko) 2014-01-17
ZA201308280B (en) 2014-07-30
LT2706982T (lt) 2018-05-25
HK1255428A1 (en) 2019-08-16
DE202012013606U1 (de) 2018-04-18
US20210338574A1 (en) 2021-11-04
CN103764119A (zh) 2014-04-30
KR20170010078A (ko) 2017-01-25
TR201802716T4 (tr) 2018-03-21
JP2014513683A (ja) 2014-06-05
RU2587051C2 (ru) 2016-06-10
HUE036465T2 (hu) 2018-07-30
CA2835940C (en) 2020-08-04
AU2016204880B2 (en) 2017-11-23
MY194947A (en) 2022-12-27
TWI486161B (zh) 2015-06-01
DK2706982T3 (en) 2018-03-12
WO2012156317A2 (en) 2012-11-22
US11020343B2 (en) 2021-06-01
US20150018379A1 (en) 2015-01-15
PH12016501342A1 (en) 2018-06-11
US11806428B2 (en) 2023-11-07
AU2012257785A1 (en) 2013-11-28
PH12016501342B1 (en) 2018-06-11
AU2012257785B2 (en) 2016-04-14
EP2706982A2 (en) 2014-03-19
PT2706982T (pt) 2018-03-08
EP3320893A1 (en) 2018-05-16
DK201800034U1 (da) 2018-05-25
SMT201800105T1 (it) 2018-05-02
WO2012156317A3 (en) 2013-05-10
CN107260672A (zh) 2017-10-20
CA2835940A1 (en) 2012-11-22
TW201311244A (zh) 2013-03-16
CO6821959A2 (es) 2013-12-31
PH12013502313A1 (en) 2022-04-08
ES2661838T3 (es) 2018-04-04
IL229409B (en) 2020-10-29
US20170304192A1 (en) 2017-10-26
BR112013029126A2 (pt) 2017-02-07
MX354249B (es) 2018-02-20
IL229409A0 (en) 2014-01-30
MX2013013276A (es) 2014-08-07
NZ617442A (en) 2015-03-27
UA110974C2 (uk) 2016-03-10
EP2706982B2 (en) 2021-03-10
JP2016128453A (ja) 2016-07-14
US20170231904A1 (en) 2017-08-17
RU2657441C1 (ru) 2018-06-13
DK2706982T4 (da) 2021-05-10
RS57054B1 (sr) 2018-05-31
KR101698182B1 (ko) 2017-01-19
AT16553U1 (de) 2020-01-15
CY1120399T1 (el) 2019-07-10
PL2706982T3 (pl) 2018-07-31
JP2018150336A (ja) 2018-09-27
US20150126540A1 (en) 2015-05-07
ES2661838T5 (es) 2021-11-18

Similar Documents

Publication Publication Date Title
SI2706982T1 (en) Intranasal pharmaceutical dosage forms comprising naloxone
JP6219271B2 (ja) 治療の方法
BR112012018061A2 (pt) processo de comando de um sistema de dosagem e de mistura de um produto com vários componentes, o sistema de dosagem e de mistura, e instalação de pulverização ou de extrusão que o compreende
WO2013038267A8 (en) Tamper resistant pharmaceutical formulations
JP2014516081A5 (enExample)
WO2008027993A3 (en) Drug delivery systems comprising solid solutions of weakly basic drugs
PE20081578A1 (es) Formulacion en polvo de valganciclovir
RU2019118465A (ru) Композиции и способы лечения передозировки опиоидами
BR112013024092A2 (pt) sistema de entrega de névoa e atomização de água
US20110236490A1 (en) Treatment or prevention of viral infection by chlorination
HRP20231302T1 (hr) Način davanja hipnotika/sedativa
HRP20130946T1 (hr) Olopatadin nazalni sprej, namijenjen upotrebi kod djece
HRP20221185T1 (hr) Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom
HRP20120812T1 (hr) Upotreba soli acetilsalicilne kiseline u lijeäśenju virusnih infekcija
HRP20200661T1 (hr) Razine ceramida u liječenju i prevenciji infekcija
HRP20231438T1 (hr) Formulacije oksitocina koje sadrže magnezij i načini uporabe
ATE507818T1 (de) Orale verabreichung eines calcitonins
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
HRP20200473T1 (hr) Dimetilaminomikeliolid za uporabu u tretmanu pulmonarne fibroze
Misik et al. Nebulizer particle size distribution measured by various methods
WO2010066437A3 (de) Wässrige zusammensetzung enthaltend dexpanthenol und natriumchlorid
FI3976012T3 (fi) Ketamiinin intranasalinen annostus klusteripäänsärkypotilaille
WO2008002191A3 (fr) Agent et procédé favorisant l'augmentation de l'activité sexuelle d'un être humain
TWM534609U (zh) 霧化器及其咬嘴
WO2014054978A2 (ru) Стабильный комбинированный раствор фенотерола гидробромида и ипратропия бромида